We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+13.49%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.34B
AUM Growth
-$346M
Cap. Flow
-$728M
Cap. Flow %
-21.78%
Top 10 Hldgs %
68.3%
Holding
475
New
106
Increased
41
Reduced
44
Closed
201

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$447M
2
CYBR
CyberArk
CYBR
+$424M
3
GTLS
Chart Industries
GTLS
+$243M
4
IPG
Interpublic Group of Companies
IPG
+$96.3M
5
COOP
Mr. Cooper
COOP
+$67.2M

Top Sells

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$288M
2
SKX
Skechers
SKX
+$227M
3
BPMC
Blueprint Medicines
BPMC
+$220M
4
CHX
ChampionX
CHX
+$187M
5
ANSS
Ansys
ANSS
+$173M

Sector Composition

Rank Sector Weight
1 Technology 21.6%
2 Industrials 16.01%
3 Healthcare 15.52%
4 Communication Services 12.09%
5 Financials 10.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
276
AnaptysBio
ANAB
$1.68B
– –
-38,528
Closed -$855K
ANNX icon
277
Annexon
ANNX
$923M
– –
-492,698
Closed -$1.18M
ANSS
278
DELISTED
Ansys
ANSS
– –
-492,829
Closed -$173M
ARGX icon
279
argenx
ARGX
$64.6B
– –
-2,191
Closed -$1.21M
ARVN icon
280
Arvinas
ARVN
$614M
– –
-50,000
Closed -$368K
ASML icon
281
ASML
ASML
$659B
– –
-3,000
Closed -$2.4M
ATEC icon
282
Alphatec Holdings
ATEC
$1.46B
– –
-119,094
Closed -$1.32M
AUTL
283
Autolus Therapeutics
AUTL
$596M
– –
-565,000
Closed -$1.29M
AXGN icon
284
CALL
Axogen
AXGN
$2.6B
– –
-50,000
Closed -$23.8K
AXGN icon
285
Axogen
AXGN
$2.6B
– –
-81,429
Closed -$884K
AXSM icon
286
Axsome Therapeutics
AXSM
$10.8B
– –
-6,400
Closed -$668K
AZN icon
287
AstraZeneca
AZN
$252B
– –
-21,499
Closed -$3M
BA icon
288
Boeing
BA
$168B
– –
-27,675
Closed -$5.8M
BAX icon
289
Baxter International
BAX
$13.4B
– –
-88,787
Closed -$2.69M
BBIO icon
290
BridgeBio Pharma
BBIO
$14.6B
– –
-13,771
Closed -$595K
BCYC
291
CALL
Bicycle Therapeutics
BCYC
$301M
– –
-50,000
Closed -$11.3K
BCYC
292
Bicycle Therapeutics
BCYC
$301M
– –
-143,800
Closed -$999K
BDX icon
293
Becton Dickinson
BDX
$50.3B
– –
-15,107
Closed -$2.6M
BEKE icon
294
KE Holdings
BEKE
$19.8B
– –
-51,814
Closed -$919K
BIIB icon
295
CALL
Biogen
BIIB
$32.6B
– –
-20,000
Closed -$30K
BKR icon
296
Baker Hughes
BKR
$63B
– –
-80,000
Closed -$3.07M
BMY icon
297
CALL
Bristol-Myers Squibb
BMY
$136B
– –
-40,000
Closed -$9K
BORR
298
CALL
Borr Drilling
BORR
$1.4B
– –
-200,000
Closed -$5K
BPMC
299
DELISTED
Blueprint Medicines
BPMC
– –
-1,713,587
Closed -$220M
BTI icon
300
British American Tobacco
BTI
$119B
– –
-82,631
Closed -$3.91M
10 11
12
13 14

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q3 2025 Portfolio in Review

As of Q3 2025, UBS O'Connor held 475 positions worth $3.34B, down 9.4% from $3.69B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

UBS O'Connor withdrew a net $728M in Q3 2025, closing 201 positions and reducing 44 holdings. Its most notable exit was Walgreens Boots Alliance, an estimated $288M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 14% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, UBS O'Connor opened a new position in Verona Pharma worth $457M.

  • UBS O'Connor's largest Q3 2025 buy was Verona Pharma: 4,283,462 shares worth $457M.
  • UBS O'Connor added most to Interpublic Group of Companies in Q3 2025, an estimated $96.3M increase.
  • UBS O'Connor's biggest Q3 2025 reduction was Kellanova, cutting an estimated $110M.
  • UBS O'Connor fully exited Walgreens Boots Alliance in Q3 2025, selling an estimated $288M.
  • UBS O'Connor's ten largest holdings make up 68% of its $3.34B portfolio in Q3 2025.
  • UBS O'Connor opened 106 new positions and closed 201 in Q3 2025.
  • UBS O'Connor's portfolio value fell 9.4% quarter-over-quarter to $3.34B.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.